Ciltacabtagene Autoleucel Is a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM

Conference Correspondent —December 16, 2020

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor (CAR) T-cell therapy directed against 2 discrete B-cell maturation antigen (BCMA) epitopes. Updated data from the phase 1b portion of CARTITUDE-1, which is evaluating cilta-cel in a patient population in the United States, along with initial phase 2 data, are presented. The primary objective of the phase 1b portion was to assess safety and determine a dose to be used in the phase 2 investigation. The primary objective of the phase 2 portion was to evaluate efficacy.

Eligible adults in this study had measurable disease, Eastern Cooperative Oncology Group performance status ≤1, received ≥3 prior regimens, or were double-refractory to a proteasome inhibitor and an immunomodulatory drug. Patients also had received an anti-CD38 antibody. After lymphodepletion with cyclophosphamide and fludarabine daily for 3 days followed by 2 to 4 days of rest, a single infusion of cilta-cel at a target dose of 0.75 × 106 (range, 0.5-1.0 × 106) CAR+ viable T-cells/kg was administered.

A total of 97 patients received cilta-cel (phase 1b, 29; phase 2, 68) at a median dose of 0.71 × 106 (range, 0.51-1.95 × 106) CAR+ viable T-cells/kg at the time of the latest data cutoff. The median age of patients in the study was 61 years, and 59% of patients were male. Patients had received a median of 6 prior lines of therapy, with 83.5% of patients being penta-exposed, 87.6% triple-refractory, 42.3% penta-refractory, and 99% refractory to their last line of therapy. The median follow-up duration in this study was 8.8 months.

The observed overall response rate was 96.9%. A complete response rate was observed in 67% of patients, a very good partial response rate in 25.8%, and a partial response rate in 4.1%. M protein was reduced in all patients. The median time to first response was 1.0 month (range, 0.9-5.8; 80.4% ≤1.0 months), and the median time to complete response or better was 1.8 months (range, 0.9-12.5; 74.1% ≤3.0 months), with responses deepening over time. At the time of data cutoff, the median duration of response was not reached. Of 57 patients evaluable for minimal residual disease (MRD), 93% were MRD negative at 10-5. The 12-month progression-free survival (PFS) rate was 76.6%. The median PFS has not yet been reached. The 12-month overall survival (OS) rate was 88.5%, and the median OS has also not been reached.

There were 9 deaths in the study resulting from adverse events (1 for all the following: cytokine release syndrome [CRS]/hemophagocytic lymphohistiocytosis, neurotoxicity, respiratory failure, pneumonia, and lung abscess; 2 for both sepsis and/or septic shock and acute myelogenous leukemia) and 5 of which resulted from progressive disease. A total of 94.8% of patients experienced CRS (grade 3/4, 4.1%), 95.9% of patients experienced neutropenia (all but 1 being grade 3/4), 81.4% of patients experienced anemia (grade 3/4, 68.0%), and 79.4% of patients experienced thrombocytopenia (grade 3/4, 59.8%). Median time to onset and duration of CRS were 7.0 days and 4.0 days, respectively. Neurotoxicity due to CAR T-cell therapy was experienced by 20.6% of patients (grade 3/4, 10.3%). Maximum peripheral expansion of CAR+ T-cells was observed at 14 days, and 67% of patients at 6 months had cilta-cel CAR+ T-cells below the level of quantification (2 cells/μL) in peripheral blood.

The preliminary results from the phase 1b/2 CARTITUDE-1 study revealed early, deep, and durable responses in these heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). The safety profile was consistent with prior studies. Cilta-cel is currently being evaluated in other multiple myeloma populations.


Abstract 177. ASH 2020. December 5, 2020. CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma.

Related Articles
Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Conference Correspondent
The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%.
ANCHOR: Melflufen plus Dexamethasone and Daratumumab or Bortezomib in RRMM Refractory to an Immunomodulatory Drug and/or a Proteasome Inhibitor
Conference Correspondent
The updated efficacy and safety data from the ANCHOR study of melflufen plus dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging efficacy that was well-tolerated.
APOLLO: Combination of Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM
Conference Correspondent
Daratumumab + pomalidomide and dexamethasone reduced the risk for disease progression and death without additional safety signals versus pomalidomide and dexamethasone alone for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.
Last modified: December 16, 2020

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code